190 related articles for article (PubMed ID: 21861826)
1. P2Y12 receptor antagonists in acute coronary syndrome: clinical implications of pharmacologic and pharmacogenetic differences.
Singh M; Adigopula S; Ahmad N; Arora R; Khosla S
Recent Pat Cardiovasc Drug Discov; 2011 Sep; 6(3):207-14. PubMed ID: 21861826
[TBL] [Abstract][Full Text] [Related]
2. Pleiotropic effects of platelet P2Y12 receptor inhibitors: fact or fiction?
Moulias A; Xanthopoulou I; Alexopoulos D
Curr Pharm Des; 2014; 20(28):4597-604. PubMed ID: 24730531
[TBL] [Abstract][Full Text] [Related]
3. Platelet Inhibition Agents: Current and Future P2Y12 Receptor Antagonists.
Tang J; Li MP; Zhou HH; Chen XP
Curr Vasc Pharmacol; 2015; 13(5):566-77. PubMed ID: 25440595
[TBL] [Abstract][Full Text] [Related]
4. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.
Tan GM; Lam YY; Yan BP
Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998
[TBL] [Abstract][Full Text] [Related]
5. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
[TBL] [Abstract][Full Text] [Related]
6. P2Y
Bonello L; Angiolillo DJ; Aradi D; Sibbing D
Circulation; 2018 Oct; 138(15):1582-1596. PubMed ID: 30354508
[TBL] [Abstract][Full Text] [Related]
7. P2Y12 inhibitors in acute coronary syndrome: when to give them and when to prolong their use.
Grotti S; Bolognese L
J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e9-e12. PubMed ID: 29538137
[No Abstract] [Full Text] [Related]
8. Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
Zhou Y; Wang Y; Wu Y; Huang C; Yan H; Zhu W; Xu W; Zhang L; Zhu J
BMC Cardiovasc Disord; 2017 Jun; 17(1):157. PubMed ID: 28619104
[TBL] [Abstract][Full Text] [Related]
9. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.
Mangiacapra F; Patti G; Barbato E; Peace AJ; Ricottini E; Vizzi V; Gatto L; D'Ambrosio A; De Bruyne B; Wijns W; Di Sciascio G
JACC Cardiovasc Interv; 2012 Mar; 5(3):281-9. PubMed ID: 22440493
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of residual platelet reactivity in patients treated with platelet P2Y12 inhibitors.
Thomas MR; Storey RF
Vascul Pharmacol; 2016 Sep; 84():25-7. PubMed ID: 27275527
[TBL] [Abstract][Full Text] [Related]
11. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
[TBL] [Abstract][Full Text] [Related]
12. Response variability to P2Y12 receptor inhibitors: expectations and reality.
Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
[TBL] [Abstract][Full Text] [Related]
13. Modern antiplatelet agents in coronary artery disease.
Power RF; Hynes BG; Moran D; Yagoub H; Kiernan G; Ruggiero NJ; Kiernan TJ
Expert Rev Cardiovasc Ther; 2012 Oct; 10(10):1261-72. PubMed ID: 23190065
[TBL] [Abstract][Full Text] [Related]
14. [The role of direct-acting P2Y12 inhibitors in acute coronary syndrome].
Buriakina TA; Zateĭshchikov DA
Kardiologiia; 2012; 52(4):74-9. PubMed ID: 22839520
[TBL] [Abstract][Full Text] [Related]
15. Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?
Alexopoulos D; Katogiannis K; Sfantou D; Lekakis J
Platelets; 2018 May; 29(3):228-237. PubMed ID: 29022423
[TBL] [Abstract][Full Text] [Related]
16. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
[TBL] [Abstract][Full Text] [Related]
17. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.
Tantry US; Bonello L; Aradi D; Price MJ; Jeong YH; Angiolillo DJ; Stone GW; Curzen N; Geisler T; Ten Berg J; Kirtane A; Siller-Matula J; Mahla E; Becker RC; Bhatt DL; Waksman R; Rao SV; Alexopoulos D; Marcucci R; Reny JL; Trenk D; Sibbing D; Gurbel PA;
J Am Coll Cardiol; 2013 Dec; 62(24):2261-73. PubMed ID: 24076493
[TBL] [Abstract][Full Text] [Related]
18. New antiplatelet agents in the treatment of acute coronary syndromes.
Sabouret P; Taiel-Sartral M
Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
[TBL] [Abstract][Full Text] [Related]
19. Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study.
Deharo P; Quilici J; Bonnet G; Grosdidier C; Morange P; Alessi MC; Bonnet JL; Cuisset T
Platelets; 2016 Dec; 27(8):791-795. PubMed ID: 27275528
[TBL] [Abstract][Full Text] [Related]
20. Pleiotropic effects of antiplatelet treatment in patients with coronary artery disease.
Siasos G; Mourouzis K; Tousoulis D
Hellenic J Cardiol; 2018; 59(6):344-346. PubMed ID: 29990542
[No Abstract] [Full Text] [Related]
[Next] [New Search]
